Natixis Advisors L.P. Sells 57,240 Shares of Boston Scientific Co. (NYSE:BSX)

Natixis Advisors L.P. lessened its stake in shares of Boston Scientific Co. (NYSE:BSX) by 3.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,718,187 shares of the medical equipment provider’s stock after selling 57,240 shares during the quarter. Natixis Advisors L.P.’s holdings in Boston Scientific were worth $99,327,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of BSX. First Horizon Advisors Inc. raised its holdings in Boston Scientific by 7.7% in the 4th quarter. First Horizon Advisors Inc. now owns 4,970 shares of the medical equipment provider’s stock valued at $287,000 after buying an additional 356 shares during the last quarter. West Family Investments Inc. raised its holdings in Boston Scientific by 12.2% during the 4th quarter. West Family Investments Inc. now owns 4,354 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 473 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Boston Scientific by 0.6% in the 4th quarter. Fisher Asset Management LLC now owns 3,993,388 shares of the medical equipment provider’s stock worth $230,858,000 after purchasing an additional 22,946 shares during the period. First Trust Direct Indexing L.P. boosted its stake in shares of Boston Scientific by 6.7% in the 4th quarter. First Trust Direct Indexing L.P. now owns 35,024 shares of the medical equipment provider’s stock valued at $2,025,000 after purchasing an additional 2,187 shares during the last quarter. Finally, Summit Financial LLC boosted its position in Boston Scientific by 2.9% during the fourth quarter. Summit Financial LLC now owns 15,769 shares of the medical equipment provider’s stock valued at $912,000 after acquiring an additional 445 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the transaction, the executive vice president now owns 56,508 shares in the company, valued at $3,779,820.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,384 shares of company stock valued at $5,395,560. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

Shares of NYSE:BSX traded up $0.83 during midday trading on Friday, hitting $72.86. The company had a trading volume of 7,452,079 shares, compared to its average volume of 6,661,660. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The business’s 50-day simple moving average is $68.30 and its 200-day simple moving average is $61.11. The stock has a market cap of $109.29 billion, a price-to-earnings ratio of 61.22, a price-to-earnings-growth ratio of 2.48 and a beta of 0.77. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $74.39.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. The firm had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. During the same period in the previous year, the firm earned $0.45 EPS. On average, research analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent research reports. Oppenheimer increased their target price on Boston Scientific from $58.00 to $68.00 and gave the stock a “market perform” rating in a report on Thursday, February 1st. JPMorgan Chase & Co. upped their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. UBS Group lifted their price target on Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. TD Cowen increased their price objective on Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research note on Thursday, March 7th. Finally, StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Three investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $75.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.